 - In Europe, advanced ovarian cancer patients are treated in first line with optimal debulking surgery followed by carboplatinpaclitaxel regimen plus bevacizumab during chemotherapy and as maintenance for a total à 15 months. The addition of bevacizumab is a standard for the patients with residual disease. 